Addex Therapeutics Ltd (SWX:ADXN)
Switzerland
· Delayed Price · Currency is CHF 0.0588
0.00 (0.00%)
May 27, 2025, 5:30 PM CET
Addex Therapeutics Revenue
In the year 2024, Addex Therapeutics had annual revenue of 410.04K CHF, down -74.64%. Addex Therapeutics had revenue of 1.51K in the quarter ending December 31, 2024, a decrease of -99.02%.
Revenue
410.04K
Revenue Growth
-74.64%
P/S Ratio
14.10
Revenue / Employee
17.83K
Employees
23
Market Cap
5.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 410.04K | -1.21M | -74.64% |
| Dec 31, 2023 | 1.62M | 172.23K | 11.92% |
| Dec 31, 2022 | 1.44M | -1.71M | -54.18% |
| Dec 31, 2021 | 3.15M | -725.84K | -18.71% |
| Dec 31, 2020 | 3.88M | 1.05M | 36.89% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.40B |
| Novartis AG | 47.05B |
| Lonza Group AG | 6.57B |
| Alcon | 8.77B |
| Galderma Group AG | 4.02B |
| Sandoz Group AG | 9.41B |
| Straumann Holding AG | 2.50B |
| Sonova Holding AG | 3.87B |
Addex Therapeutics News
- 15 days ago - Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies - GlobeNewsWire
- 27 days ago - Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery - GlobeNewsWire
- 4 weeks ago - Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Addex Therapeutics reports FY results - Seeking Alpha
- 4 weeks ago - Addex Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 - GlobeNewsWire
- 4 months ago - Addex to Present at the 2025 Swiss Equities Baader Conference - GlobeNewsWire
- 6 months ago - Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ... - GuruFocus